Abstract: Various compositions and diagnostic devices for the detection of nucleic acids are provided. Also provided are systems comprising the same, and methods of using the same. In some embodiments, compositions and devices comprise or are configured to be used in combination with one or more of a guide nucleic acid, a programmable nuclease, and reporters. In some embodiments, presence of at least one sequence of interest is determined by detecting a signal produced upon cleavage of the reporters.

Abstract: In one or more embodiments, a computing device is configured to modify an original video by applying a machine learning model. The computing device obtains multiple training data sets, with each particular training data set including an original video and a corresponding modified video. One or more frames from the original video are cropped to generate corresponding frames in the corresponding modified video. The computing device trains a machine learning model, using the training data sets, to generate modified videos from original videos such that one or more frames in the original videos are modified to generate corresponding frames in respective modified videos. Once the machine learning model is trained, the computing device obtains a target original video and applies the trained machine learning model to the target original video to generate a target modified video.

Abstract: Aspects of the present invention relate to a dynamic woven material that is capable of undergoing a dimensional change in response to an external stimulus. The dynamic woven material comprises a plurality of discrete woven cells, where each woven cell comprises a reactive region and a non-reactive region. The reactive region changes from a first physical state to a second physical state when the woven material is exposed to the external stimulus. The woven material may be formed with zonal stretch properties by varying the areas occupied by the reactive region and the non-reactive region in each woven cell. For example, the bigger the area occupied by the reactive region in the woven cells in a particular zone of the dynamic woven material, the higher the level of stretch in the particular zone may be. Exemplary products manufactured from the dynamic woven material include, for example, articles of footwear.

Abstract: IC interconnect structures including subtractively patterned features. Feature ends may be defined through multiple patterning of multiple cap materials for reduced misregistration. Subtractively patterned features may be lines integrated with damascene vias or with subtractively patterned vias, or may be vias integrated with damascene lines or with subtractively patterned lines. Subtractively patterned vias may be deposited as part of a planar metal layer and defined currently with interconnect lines. Subtractively patterned features may be integrated with air gap isolation structures. Subtractively patterned features may be include a barrier material on the bottom, top, or sidewall. A bottom barrier of a subtractively patterned features may be deposited with an area selective technique to be absent from an underlying interconnect feature. A barrier of a subtractively patterned feature may comprise graphene or a chalcogenide of a metal in the feature or in a seed layer.

Abstract: A heat press docking station base (52) comprises a nest portion (75) and one or more legs (58). The nest portion (52) includes a body shell (60, 62) and a perforated floor (54). The body shell (60, 62) includes a lower surface (63). The perforated floor (54) is connected to the body shell (60, 62). The one or more legs (58) extend from a lower surface (63) of the body shell (60, 62).

Abstract: The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: The invention provides unsaturated phosphonates of Formula I or a tautomer or pharmaceutically acceptable salt thereof, as described herein, as well as pharmaceutical compositions comprising the compounds, and therapeutic methods comprising administering the compounds. The compounds have anti-viral properties and are useful for treating viral infections (e.g. HCV) in animals (e.g. humans).

Abstract: The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: The invention is related to phosphorus substituted nucleoside compounds and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: A compound of Formula I, Formula II, Formula III, or Formula IV: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, therapeutic compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Abstract: The invention is related to compounds of Formula I: or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Abstract: The invention is related to compounds of Formula I: or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Abstract: The invention provides unsaturated phosphonates of Formula I or a tautomer or pharmaceutically accepatble salt thereof, as described herein, as well as pharmaceutical compositions comprising the compounds, and therapeutic methods comprising administering the compounds. The compounds have anti-viral properties and are useful for treating viral infections (e.g. HCV) in animals (e.g. humans).

Abstract: The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: The invention is related to phosphorus substituted therapeutic agents, compositions containing such phosphorus substituted agents, and therapeutic methods that include the administration of such phosphorus substituted agents, as well as to processes and intermediates useful for preparing such agents.

Abstract: The invention is related to compounds of Formula I or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Abstract: The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.